Combilipen® NEO (Solution) Instructions for Use
Marketing Authorization Holder
Pharmstandard-UfaVITA OJSC (Russia)
ATC Code
A11DB (Vitamin B1 in combination with vitamins B6 and/or B12)
Dosage Form
| Combilipen® NEO | Solution for intramuscular injection: amp. 2 ml 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for intramuscular injection in the form of a transparent, pinkish-red liquid with a characteristic odor.
| 1 amp. (2 ml) | |
| Thiamine hydrochloride | 100 mg |
| Pyridoxine hydrochloride | 100 mg |
| Cyanocobalamin | 1 mg |
Excipients: diethanolamine – 5 mg, water for injection – up to 2 ml.
2 ml – ampoules of light-protective glass (5) – contour cell packaging (1) – cardboard packs.
2 ml – ampoules of light-protective glass (5) – contour cell packaging (2) – cardboard packs.
Clinical-Pharmacological Group
B complex vitamins
Pharmacotherapeutic Group
Vitamins; vitamin B1 and its combinations with vitamins B6 and B12; vitamin B1 in combination with vitamins B6 and/or B12
Pharmacological Action
A complex of B vitamins. Thiamine (B1), pyridoxine (B6) and Cyanocobalamin (B12) are neurotropic substances and play a special role as coenzymes in the intermediate metabolism occurring in the central and peripheral nervous system.
Like other vitamins, they are essential food components that the body is unable to synthesize on its own.
The therapeutic use of vitamins B1, B6 and B12 compensates for the often existing insufficient intake of vitamins from food, which ensures the presence of the necessary amount of coenzymes in the body. The use of B vitamins in the form of a complex increases their therapeutic efficacy, since the efficacy of the combination exceeds the efficacy of individual components.
The therapeutic use of these vitamins in various diseases of the nervous system is aimed, on the one hand, at compensating for an existing deficiency (possibly due to the body’s increased need directly caused by the disease) and, on the other hand, at stimulating natural mechanisms aimed at recovery.
At the same time, the indirect analgesic effect of the B vitamin complex has a beneficial effect on the therapeutic outcome.
Pharmacokinetics
After oral administration, thiamine undergoes dose-dependent transport, the mechanism of which is dual in nature: active absorption at concentrations up to 2 µmol/L and passive diffusion at concentrations above 2 µmol/L. Phosphorylation of thiamine occurs in the liver. T1/2 is about 4 hours.
The human body contains about 30 mg of thiamine. Given the rapid metabolism, it is eliminated within 4-10 days.
Pyridoxine is absorbed very quickly, mainly in the upper intestine, and is eliminated within a maximum of 2-5 hours. Performing the function of a coenzyme requires phosphorylation of pyridoxine. Pyridoxine in the phosphorylated form (pyridoxal phosphate) is almost 80% bound to plasma proteins.
The human body contains about 40-150 mg. 1.7-3.6 mg is excreted in the urine per day.
Cyanocobalamin is absorbed from the gastrointestinal tract through 2 mechanisms: 1) release under the action of gastric juice and rapid binding to intrinsic factor; 2) passive diffusion through the intestinal epithelium regardless of intrinsic factor.
At doses greater than 1.5 µg, the latter mechanism plays a significant role. In patients with B12-deficiency anemia, reabsorption after oral administration is approximately 1% of 100 µg or more.
Excess cyanocobalamin accumulates in the liver.
Cyanocobalamin is excreted from the liver with bile into the intestine and is largely reabsorbed during enterohepatic circulation. The metabolic rate of Cyanocobalamin per day is 2.5 µg.
Indications
As part of complex therapy for the following neurological diseases: neuritis and neuralgia – trigeminal neuralgia; facial nerve paresis; intercostal neuralgia; pain syndrome caused by spinal diseases (lumboischialgia, plexopathy, radicular syndrome caused by degenerative changes of the spine); herpes zoster; neuropathic pain caused by polyneuropathy including diabetic and alcoholic).
ICD codes
| ICD-10 code | Indication |
| B02.2 | Herpes zoster with other complications of the nervous system |
| G50.0 | Trigeminal neuralgia |
| G51 | Disorders of facial nerve |
| G54 | Lesions of nerve roots and plexuses |
| G58.0 | Intercostal neuropathy |
| G60 | Hereditary and idiopathic neuropathy |
| G61 | Inflammatory polyneuropathy |
| G62.1 | Alcoholic polyneuropathy |
| G63.2 | Diabetic polyneuropathy |
| M42 | Spinal osteochondrosis |
| M47 | Spondylosis |
| M54.1 | Radiculopathy |
| M54.3 | Sciatica |
| M54.4 | Lumbago with sciatica |
| M79.2 | Neuralgia and neuritis, unspecified |
| ICD-11 code | Indication |
| 1E91.40 | Acute trigeminal neuropathy due to herpes zoster |
| 1E91.41 | Acute herpetic geniculate ganglionitis |
| 1E91.4Y | Other specified acute cranial nerve neuropathy due to herpes zoster |
| 1E91.4Z | Acute cranial nerve neuropathy due to herpes zoster, unspecified |
| 1E91.Z | Herpes zoster, unspecified |
| 8B82.0 | Trigeminal neuralgia |
| 8B88.Z | Lesions of facial nerve, unspecified |
| 8B93.Z | Radiculopathy, unspecified |
| 8B9Z | Diseases of nerve roots or plexuses, unspecified |
| 8C01.Z | Inflammatory polyneuropathy, unspecified |
| 8C03.0 | Diabetic polyneuropathy |
| 8C12.0 | Intercostal neuropathy |
| 8C2Y | Other specified hereditary neuropathy |
| 8C4Z | Disorders of nerve roots, plexuses or peripheral nerves, unspecified |
| 8D44.0 | Alcoholic polyneuropathy |
| 8E4A.1 | Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system |
| FA85.Z | Defects of vertebral end-plates, unspecified |
| FA8Z | Degenerative disease of spine, unspecified |
| FB56 | Specified soft tissue diseases, not elsewhere classified |
| ME84.20 | Lumbago with sciatica |
| ME84.3 | Sciatica |
| 1E91.3 | Herpes zoster with involvement of the central nervous system |
| 1D02.1 | Viral myelitis |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Take orally 1 single dose 3 times/day. The duration of treatment is determined by the doctor and averages 1-1.5 months. Dose adjustment is recommended for therapy lasting more than 4 weeks.
Intramuscularly administer 1 single dose 1 time/day until acute symptoms are relieved. After symptom reduction or in case of moderate severity of the disease, administer 1 single dose 1-3 times a week for 2-3 weeks.
For maintenance therapy, for relapse prevention or continuation of the ongoing course of treatment, oral administration in the appropriate dosage form is recommended. The duration of treatment is determined individually by the doctor.
Adverse Reactions
From the immune system very rarely – hypersensitivity reactions, such as sweating, tachycardia.
Allergic reactions very rarely – itching, urticaria, anaphylactic shock.
From the digestive system: frequency not established – nausea, vomiting, diarrhea, abdominal pain.
From the nervous system frequency not established – long-term use (>6-12 months) of vitamin B6 at a daily dose >50 mg may cause peripheral sensory neuropathy.
Contraindications
Children under 18 years of age; hypersensitivity to the active substances of the combination.
Use in Pregnancy and Lactation
Use during pregnancy and lactation (breastfeeding) is not recommended due to the high content of vitamins.
Pediatric Use
The drug is contraindicated for use in children and adolescents under 18 years of age.
Special Precautions
If signs of peripheral sensory neuropathy (paresthesia) appear, it is necessary to adjust the dose and, if necessary, discontinue the drug.
When administering vitamin B12, the clinical picture, as well as laboratory parameters in funicular myelosis or pernicious anemia, may lose their specificity.
Drug Interactions
When used concomitantly with levodopa, pyridoxine may reduce the antiparkinsonian effect of levodopa.
Concomitant use of pyridoxine antagonists (e.g., isoniazid, hydralazine, penicillamine, or cycloserine) may increase the need for pyridoxine.
Thiamine is inactivated by fluorouracil. Fluorouracil competitively inhibits the phosphorylation of thiamine to thiamine pyrophosphate.
Antacids reduce the absorption of thiamine.
"Loop" diuretics, e.g., furosemide, can block tubular reabsorption, thus enhancing the excretion of thiamine during long-term use, which leads to a decrease in thiamine levels in the blood.
Ingestion of alcohol and black tea leads to reduced absorption of thiamine.
Beverages containing sulfites (e.g., wine) enhance the degradation of thiamine.
Storage Conditions
Store at 2°C (36°F) to 8°C (46°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer